NO20092977L - Stabile, farmasoytiske legemiddelaerosoler - Google Patents

Stabile, farmasoytiske legemiddelaerosoler

Info

Publication number
NO20092977L
NO20092977L NO20092977A NO20092977A NO20092977L NO 20092977 L NO20092977 L NO 20092977L NO 20092977 A NO20092977 A NO 20092977A NO 20092977 A NO20092977 A NO 20092977A NO 20092977 L NO20092977 L NO 20092977L
Authority
NO
Norway
Prior art keywords
drug product
container
pharmaceutical drug
fine particle
stable
Prior art date
Application number
NO20092977A
Other languages
English (en)
Norwegian (no)
Inventor
Jill K Sherwood
Joel Sequeira
Brent A Donovan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20092977L publication Critical patent/NO20092977L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20092977A 2007-02-09 2009-09-08 Stabile, farmasoytiske legemiddelaerosoler NO20092977L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/003637 WO2008097233A1 (fr) 2007-02-09 2007-02-09 Aérosols de médicaments pharmaceutiques stables

Publications (1)

Publication Number Publication Date
NO20092977L true NO20092977L (no) 2009-11-02

Family

ID=38610578

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092977A NO20092977L (no) 2007-02-09 2009-09-08 Stabile, farmasoytiske legemiddelaerosoler

Country Status (10)

Country Link
EP (2) EP2117504A1 (fr)
JP (1) JP2010518076A (fr)
KR (1) KR20100004993A (fr)
CN (1) CN101652123A (fr)
AU (1) AU2007346134A1 (fr)
BR (1) BRPI0721256A2 (fr)
CA (1) CA2677347A1 (fr)
MX (1) MX2009008572A (fr)
NO (1) NO20092977L (fr)
WO (1) WO2008097233A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011136754A1 (fr) * 2010-04-26 2011-11-03 Mahmut Bilgic Médicament mis au point pour le traitement de maladies respiratoires
KR102462058B1 (ko) * 2014-10-08 2022-11-01 잠본쏘시에떼퍼아찌오니 제제의 안정성을 증가시키기 위해 분무 건조에 의해 수득된 1종 이상의 건조 분말을 포함하는 조성물
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3701940A1 (fr) 2015-12-04 2020-09-02 Mexichem Fluor S.A. de C.V. Composition pharmaceutique
CN107961217B (zh) * 2016-10-18 2021-06-29 天津金耀集团有限公司 一种糠酸莫米松气雾剂组合物
CN109464429B (zh) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 一种吸入压力定量气雾剂药物组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
JP3264496B2 (ja) * 1996-08-29 2002-03-11 シェーリング コーポレイション クロロフルオロカーボンを含まないモメタゾンフロエートエーロゾルの処方物
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
EP1241113A1 (fr) * 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhalateur avec des moyens pour améliorer la stabilité chimique des solutions d'aerosol médicinales qu'il contient
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1878664B1 (fr) 2002-08-27 2011-03-30 Schering Corporation Procédé pour la production de formulations d'inhalation à dosage mesuré
US20050136009A1 (en) * 2003-10-20 2005-06-23 Schering Corporation Pharmaceutical compositions

Also Published As

Publication number Publication date
EP2444080A3 (fr) 2012-05-02
BRPI0721256A2 (pt) 2013-03-12
EP2444080A2 (fr) 2012-04-25
CA2677347A1 (fr) 2008-08-14
CN101652123A (zh) 2010-02-17
MX2009008572A (es) 2009-10-19
WO2008097233A1 (fr) 2008-08-14
JP2010518076A (ja) 2010-05-27
EP2117504A1 (fr) 2009-11-18
AU2007346134A1 (en) 2008-08-14
KR20100004993A (ko) 2010-01-13

Similar Documents

Publication Publication Date Title
NO20092977L (no) Stabile, farmasoytiske legemiddelaerosoler
Herrera-Cruz et al. Of yeast, mice and men: MAMs come in two flavors
Dramsi et al. Listeriolysin O-mediated calcium influx potentiates entry of Listeria monocytogenes into the human Hep-2 epithelial cell line
Gutsche et al. Secreted dengue virus nonstructural protein NS1 is an atypical barrel-shaped high-density lipoprotein
Yusupov et al. Atomic-scale simulations of reactive oxygen plasma species interacting with bacterial cell walls
Wang et al. Autophagy and cell reprogramming
Susanto et al. Mouse granzyme A induces a novel death with writhing morphology that is mechanistically distinct from granzyme B-induced apoptosis
Shen et al. Modelling cadmium‐induced cardiotoxicity using human pluripotent stem cell‐derived cardiomyocytes
RU2020105325A (ru) Культуральная среда стволовых клеток
Lee et al. Embryonic stem cells: a novel paradigm to study proteostasis?
Li et al. Honokiol inhibits LPS‐induced maturation and inflammatory response of human monocyte‐derived dendritic cells
BR112013008364A2 (pt) filtros de fumaça para dispositivos de fumar com massas porosas tendo uma carga de partícula de carbono e uma queda de pressão encapsulada
NO20075166L (no) Dendrittiske celleblandinger og fremgangsmater
Mellouk et al. Cytosolic access of intracellular bacterial pathogens: the Shigella paradigm
WO2006101633A3 (fr) Appareil et procede permettant l'identification de donnees asynchrones dans des memoires de donnees redondantes, et la resynchronisation de celles-ci
BR112012012463A2 (pt) método e aparelho para apresentação de segmentos de mídia
Kim et al. Regulatory effect of cinnamaldehyde on monocyte/macrophage‐mediated inflammatory responses
Kharlamova et al. Vapor treatment of electrospray droplets: evidence for the folding of initially denatured proteins on the sub-millisecond time-scale
Mollo et al. Targeting mitochondrial network architecture in Down syndrome and aging
BR112013028257A2 (pt) "composição de fármaco biológico, métodos de manipulação de uma composição de fármaco biológica com células vivas e de fornecer composições de células vivas em um ponto de instalação de tratamento, bem como uso de células vivas formuladas em tampão não nutritivo"
BR112012006319B8 (pt) sistema de dispensação de medicamentos automatizado, dispositivo de mão, sistema de administração de cabeceira e método para verificação da dispensação de um item
Wahlin et al. Modeling retinal dystrophies using patient-derived induced pluripotent stem cells
Ghodasara et al. Clinical translation of extracellular vesicles
Wojciechowski et al. Choice of Capping Group in Tripeptide Hydrogels Influences Viability in the Three‐Dimensional Cell Culture of Tumor Spheroids
Gianì et al. The possible role of cancer stem cells in the resistance to kinase inhibitors of advanced thyroid cancer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

FC2A Withdrawal, rejection or dismissal of laid open patent application